# The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

> **NCT00065325** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 694 (actual)

## Conditions studied

- Locally Advanced Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT00065325
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2006-06
- **Final completion:** 2014-09
- **Target enrollment:** 694 (ACTUAL)
- **Last updated:** 2015-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065325, "The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00065325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*